argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: GlobeNewswire
September 3, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the Morgan Stanley 17th Annual Global Healthcare Conference on Monday, September 9, 2019 at 10:30 am ET in New York. The live webcast may be accessed on the homepage of the argenx website at www.argenx.com. Shortly after the presentation, a replay of the webcast will be available for 90 days on the argenx website. About argenxargenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-clas
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenx SE (NASDAQ: ARGX) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $697.00 price target on the stock.MarketBeat
- argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in ChinaGlobeNewswire
- argenx SE (NASDAQ: ARGX) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $715.00 price target on the stock.MarketBeat
- argenx SE (NASDAQ: ARGX) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $715.00 price target on the stock.MarketBeat
- argenx to Participate at Upcoming Investor ConferencesGlobeNewswire
ARGX
Earnings
- 10/31/24 - Beat
ARGX
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/12/24 - Form 6-K
- ARGX's page on the SEC website